[Intracranial hypertension in a newborn treated with quinolone].
BACKGROUND
Fluoroquinolones have not received administrative authorization for use in children, but because of multiresistant pathogens in neonatal intensive care, floroquinolones may be the only alternative.


METHODS
A premature infant exclusively nourished by parenteral nutrition developed enterobacteria sepsis. Ceftazidine was given initially but resistance led to the prescription of fluoroquinolone. Signs of intracranial hypertension developed 3 days after onset of fluoroquinolone treatment and regressed 48 hours after its withdrawal.


CONCLUSIONS
The main potential adverse effects with fluoroquinone in the newborn are arthropathy, photosensitivity, discoloration of the teeth and neurological disorders. Intracranial hypertension is a known complication of nalidixic acid both in adults and children, but to our knowledge has not been previously with floroquinolone in the newborn.
Bedu
A
A
Service de Néonatologie, Hôpital Robert Debré, Paris.
Naar
I
I
Farnoux
C
C
Brisse
H
H
Le Huidoux
P
P
Aujard
Y
Y
D042462:4-Quinolones; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D016470:Bacteremia / Q000188:drug therapy*; D002442:Ceftazidime / Q000627:therapeutic use; D002648:Child; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D024841:Fluoroquinolones; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019586:Intracranial Hypertension / Q000139:chemically induced*; D008297:Male; D010288:Parenteral Nutrition; D015363:Quinolones / Q000009:adverse effects*; D012075:Remission, Spontaneous; D015366:Pefloxacin
D042462:4-Quinolones; D000890:Anti-Infective Agents; D002442:Ceftazidime; D024841:Fluoroquinolones; D015363:Quinolones; D015366:Pefloxacin
Hypertension intracrânienne chez un nouveau-né traité par quinolones.